AVBP Overview
Upcoming Projects (AVBP)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AVBP)
-
A Second Look: Discussing the potential of Arrivent Biopharma's firmonertinib monotherapy and the ongoing phase 3 FURVENT study for first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC)
Tickers: AVBP, JNJ
Executed On: Jan 21, 2026 at 04:00 PM EST -
Discussing the potential of Arrivent Biopharma's firmonertinib monotherapy and the ongoing phase 3 FURVENT study for first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC)
Tickers: AVBP, JNJ
Executed On: Jan 21, 2026 at 12:00 PM EST
Upcoming & Overdue Catalysts (AVBP)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (AVBP)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
